Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma

Background: Endometrioid carcinoma (EC) and clear cell carcinoma (CC) histotypes of epithelial ovarian cancer are understudied compared with the more common high-grade serous carcinomas (HGSC). We therefore sought to characterize EC and CC transcriptomes in relation to HGSC. Methods: Following bioinformatics processing and gene abundance normalization, differential expression analysis of RNA sequence data collected on fresh-frozen tumors was completed with nonparametric statistical analysis methods (55 ECs, 19 CCs, 112 HGSCs). Association of gene expression with progression-free survival (PFS) was completed with Cox proportional hazards models. Eight additional multi-histotype expression array datasets (N = 852 patients) were used for replication. Results: In the discovery set, tumors generally clustered together by histotype. Thirty-two protein-coding genes were differentially expressed across histotype (P < 1 × 10−10) and showed similar associations in replication datasets, including MAP2K6, KIAA1324, CDH1, ENTPD5, LAMB1, and DRAM1. Nine genes associated with PFS (P < 0.0001) showed similar associations in replication datasets. In particular, we observed shorter PFS time for CC and EC patients with high gene expression for CCNB2, CORO2A, CSNK1G1, FRMD8, LIN54, LINC00664, PDK1, and PEX6, whereas, the converse was observed for HGSC patients. Conclusions: The results suggest important histotype differences that may aid in the development of treatment options, particularly those for patients with EC or CC. Impact: We present replicated findings on transcriptomic differences and how they relate to clinical outcome for two of the rarer ovarian cancer histotypes of EC and CC, along with comparison with the common histotype of HGSC. Cancer Epidemiol Biomarkers Prev; 27(9); 1101–9. ©2018 AACR.

[1]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  A. Buja,et al.  Remarks on Parallel Analysis. , 1992, Multivariate behavioral research.

[3]  Adrian E. Raftery,et al.  Model-based clustering and data transformations for gene expression data , 2001, Bioinform..

[4]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[5]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[7]  D. Huo,et al.  The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. , 2006, Cancer research.

[8]  Kathleen R. Cho,et al.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. , 2006, Cancer research.

[9]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[10]  Kathleen R. Cho,et al.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.

[11]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[12]  S. Plaxe Epidemiology of low-grade serous ovarian cancer. , 2008, American journal of obstetrics and gynecology.

[13]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[14]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[15]  W. Weichert,et al.  A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.

[16]  Kathleen R. Cho,et al.  IRS1 Regulation by Wnt/β-Catenin Signaling and Varied Contribution of IRS1 to the Neoplastic Phenotype , 2009, The Journal of Biological Chemistry.

[17]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[18]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[19]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[20]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[21]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[22]  J. Leek Asymptotic Conditional Singular Value Decomposition for High‐Dimensional Genomic Data , 2011, Biometrics.

[23]  O. Mariani,et al.  miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response , 2011, Nature Medicine.

[24]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[25]  Jae K. Lee,et al.  Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance , 2012, PloS one.

[26]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[27]  Sebastian M. Armasu,et al.  Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer , 2013, Nature Communications.

[28]  Benjamin Haibe-Kains,et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.

[29]  R. Albulescu Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. , 2013, Biomarkers in medicine.

[30]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[31]  B. Schittek,et al.  Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis , 2014, Molecular Cancer.

[32]  E. Goode,et al.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.

[33]  Y-H Wu,et al.  COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer , 2014, Oncogene.

[34]  Benjamin Frederick Ganzfried,et al.  Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. , 2014, Journal of the National Cancer Institute.

[35]  Eugenia G. Giannopoulou,et al.  CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells , 2014, Oncogene.

[36]  C. Huttenhower,et al.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. , 2014, Journal of the National Cancer Institute.

[37]  B. Karlan,et al.  POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. , 2014, Gynecologic oncology.

[38]  C. Wijmenga,et al.  Gene expression analysis identifies global gene dosage sensitivity in cancer , 2015, Nature Genetics.

[39]  Kconfab Investigators,et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015 .

[40]  M. Dietel,et al.  PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. , 2015, Anticancer research.

[41]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[42]  Yurii B. Shvetsov,et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015, Nature Genetics.

[43]  S. Leung,et al.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[44]  I. Shih,et al.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. , 2016, The American journal of pathology.

[45]  B. Karlan,et al.  "Ovarian cancers: Evolving paradigms in research and care": Report from the Institute of Medicine. , 2016, Gynecologic oncology.

[46]  T. Ørntoft,et al.  miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells , 2016, Nature communications.

[47]  Z. Dong,et al.  PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model , 2016, Oncogene.